Aspergillosis Drugs Market by Product and Geography - Forecast and Analysis 2020-2024

The aspergillosis drugs market size has the potential to grow by USD 658.48 million during 2020-2024, and the market's growth momentum will accelerate during the forecast period.

This report provides a detailed analysis of the market by product (triazoles and other therapeutics) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market's competitive landscape and offers information on several market vendors, including Abbott Laboratories, Gilead Sciences Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Mayne Pharma Group Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, and Pfizer Inc.

Market Overview

Browse TOC and LoE with selected illustrations and example pages of Aspergillosis Drugs Market

Request a FREE sample now!

Market Competitive Analysis

The aspergillosis drugs market is fragmented with several vendors offering generic therapeutics for the treatment of aspergillosis. As the development and manufacturing of novel therapeutics remain a complex and cost-intensive process, new players are not expected to enter the market easily. This is expected to help maintain the configuration of the current market vendors at the same level during the forecast period. However, a few molecules are in the Phase II stage of development for the treatment of aspergillosis. Abbott Laboratories, Gilead Sciences Inc., and GlaxoSmithKline Plc are some of the major market participants. Although the special regulatory designations will offer immense growth opportunities, the increasing popularity of generic drugs will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market position, this aspergillosis drugs market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market's competitive landscape and offers information on the products offered by various companies. Moreover, this aspergillosis drugs market analysis report also provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.

This report provides information on the production, sustainability, and prospects of several leading companies, including:

• Abbott Laboratories
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson
• Mayne Pharma Group Ltd.
• Merck & Co. Inc.
• Mylan NV
• Novartis AG
• Pfizer Inc.

Aspergillosis Drugs Market: Segmentation by Geography

For more insights on the market share of various regions Request for a FREE sample now!

North America was the largest aspergillosis drugs market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. The high prevalence of chronic diseases, such as asthma and growing awareness of aspergillosis, will significantly drive aspergillosis drugs market growth in this region over the forecast period.

36% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for aspergillosis drugs in North America. However, market growth in this region will be slower than the growth of the market in Asia and Europe.

Aspergillosis Drugs Market: Segmentation by Product

Request for a FREE sample and Get more information on the market contribution of various segments

The application of triazoles has increased over the years as they have proven effective as the first-line treatment for aspergillosis. The growth of the triazoles segment is driven by recent product approvals of novel triazoles for the treatment of aspergillosis. Furthermore, the expected approvals of new triazoles are expected to accelerate the growth of the segment. These factors will drive the growth of the segment during the forecast period.

Market growth in the triazoles segment will be faster than the growth of the market in the other therapeutics segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the aspergillosis drugs market size.

Aspergillosis Drugs Market: Key Drivers and Trends

Regulatory bodies have provided special drug designation for aspergillosis as its prevalence rate is low and pharmaceutical companies are hesitant to invest a large amount in R&D for drug discovery. These designations include Qualified Infectious Disease Product, fast-track, and orphan drug designation. These designations offer special support to pharmaceutical companies to develop therapeutics for the treatment of aspergillosis. The emergence of these regulatory designations is one of the critical reasons that will drive the aspergillosis drugs market's growth.

• The development of therapeutics with novel mechanisms that have better tolerance levels and efficacy will lead to a strong pipeline.
• The presence of multiple promising therapeutic agents in the pipeline boosts the demand for therapeutic regimens and broadens the available treatment options.
• The number of clinical trials for the development of therapeutics such as F901318 for aspergillosis such as invasive aspergillosis fungal infections is increasing.
• A strong pipeline will drive the aspergillosis drugs market to grow at a CAGR of about 4% during the forecast period.

Request for a FREE sample

Aspergillosis Drugs Market: Key Highlights of the Report for 2020-2024

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will drive aspergillosis drugs market growth during the next five years
• Precise estimation of the aspergillosis drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the aspergillosis drugs industry across Asia, Europe, North America, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of aspergillosis drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch